Safety, Tolerability, and Efficacy of Orally Administered Cannabinoids in MS
Neurol 58:1404-1407,1323, Killestein,J.,et al, 2002
Patients with Multiple Sclerosis and Risk of Type 1 Diabetes Mellitus in Sardinia,Italy: A Cohort Study
Lancet 359:1461-1465,1450, Marrosu,M.G.,et al, 2002
Efficacy and Safety of Modafinil (Provigil) for the Treatment of Fatigue in Multiple Sclerosis: A Two Centre Phase 2 Study
JNNP 72:179-183,150, Rammohan,K.W.,et al, 2002
Acquired Sexual Parphilia in Patients with Multiple Sclerosis
Arch Neurol 59:1006-1010, Frohman,E.M.,et al, 2002
Mimic Syndromes in Sporadic Cases of Progressive Spinal Muscular Atrophy
Neurol 58:1593-1596, Visser,J.,et al, 2002
Interferon Beta-1a for Early Multiple Sclerosis: CHAMPS Trial Subgroup Analyses
Ann Neurol 51:481-490, Beck,R.W.,et al, 2002
Nonmotor Fluctuations in Parkinson's Disease
Neurol 59:408-413, Witjas,T.,et al, 2002
Progressive Ventricular Enlargement in Patients with Clinically Isolated Syndromes is Associated with the Early Development of Multiple Sclerosis
JNNP 73:141-147, Dalton,C.M.,et al, 2002
Early Onset Multiple Sclerosis
Neurol 59:1006-1010, Boiko,A.,et al, 2002
MRI Predictors of Early Conversion to Clinically Definite MS in the CHAMPS Placebo Group
Neurol 59:998-1005, CHAMPS Study Group, 2002
Therapy-Related Acute Myeloblastic Leukemia After Mitoxantrone Treatment in a Patient with MS
Neurol 59:954-955, Brassat,D.,et al, 2002
Cardiac Adverse Effects Associated with Mitoxantrone (Novantrone) Therapy in Patients with MS
Neurol 59:909-913, Ghalie,R.G.,et al, 2002
Prognosis for Gross Motor Function in Cerebral Palsy
JAMA 288:1357-1363,1399, Rosenbaum,P.L., et al, 2002
Proton MR Spectroscopy of Tumefactive Demyelinating Lesions
AJNR 23:1378-1386, Saindane,A.M.,et al, 2002
Lesions of the Corpus Callosum: MR Imaging and Differential Considerations in Adults and Children
AJR 179:251-257, Bourekas,E.C.,et al, 2002
Interferon Beta but not Glatiramer Acetate Therapy Aggravates Headaches in MS
Neurol 59:636-639, Pollmann,W.,et al, 2002
Benefit of Interferon B-1a on MSFC Progression in Secondary Progressive MS
Neurol 59:679-687, Cohen,J.A.,et al, 2002
Is a "Vanishing Tumor" Always a Lymphoma?
Neurol 59:762-764, Bromberg,J.E.C.,et al, 2002
Bacterial Infection as a Cause of Multiple Sclerosis
Lancet 360:352-353, Wolfson,C. &Talbot,P., 2002
Predictors of Hemorrhagic Transformation After Intravenous Recombinant Tissue Plasminogen Activator
Stroke 33:2047-2052, Selim,M.,et al, 2002
Application of the New McDonald Criteria to Patients with Clinically Isolated Syndromes Suggestive of Mulitple Sclerosis
Ann Neurol 52:47-53, Dalton,C.M.,et al, 2002
A Practical Approach to the Diagnosis and Management of MELAS: Case Report and Review
The Neurologist 8:302-312, Thambisetty,M.,et al, 2002
T2 Hypointensity in the Deep Gray Matter of Patients With Multiple Sclerosis
Arch Neurol 59:62-68, Bakshi,R.,et al, 2002
Migraine--Current Understanding and Treatment
NEJM 346:257-270, Goadsby,P.J.,et al, 2002
Refractory Status Epilepticus
Arch Neurol 59:205-210,188, Mayer,S.A.,et al, 2002
An Open-Label Trial of Combination Therapy With Interferon B-1a and Oral Methotrexate in MS
Neurol 58:314-317, Calabresi,P.A.,et al, 2002
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
A Longitudinal Study of Abnormalities on MRI and Disability From Multiple Sclerosis
NEJM 346:158-164,199, Brex,P.A.,et al, 2002
Plasma Exchange for Severe Attacks of CNS: Demyelination: Predictors of Response
Neurol 58:143-146, Keegan,M.,et al, 2002
Predictors of Functional Disability and Mortality After Status Epilepticus
Neurol 58:139-142, Claassen,J.,et al, 2002
Problems With Diagnositc Criteria for Multiple Sclerosis
Lancet 358:1746-1747, Poser,C.M. &Brinar,V.V., 2001
Epstein-Barr Virus Antibodies and Risk of Multiple Sclerosis
JAMA 286:3083-3088,3127, Ascherio,A.,et al, 2001
The Effect of IFNB-1b on the Evolution of Enhancing Lesions in Secondary Progressive MS
Neurol 57:2185-2190, Brex,P.A.,et al, 2001
Surgical Therapy for Tremor in Multiple Sclerosis
Neurol 57:1876-1882, Matsumoto,J.,et al, 2001
Oligoclonal Band Number as a Marker for Prognosis in Multiple Sclerosis
Arch Neurol 58:2044-2045, Avasarala,J.R.,et al, 2001
Tourette's Syndrome
NEJM 345:1184-1192, Jankovic,J., 2001
Improved Accuracy of Clinical Diagnosis of Lewy Body Parkinson's Disease
Neurol 57:1497-1499, Hughes,A.J.,et al, 2001
14-3-3 Protein in the CSF as Prognostic Marker in Early Multiple Sclerosis
Neurol 57:722-724, Martinez-Yelamos,A.,et al, 2001
MRI Characteristics of the MLF in MS Patients with Chronic Internuclear Ophthalmoparesis
Neurol 57:762-768, Frohman,E.M.,et al, 2001
Nonpoliovirus Poliomyelitis Simulating Guillain-Barre Syndrome
Arch Neurol 58:1460-1464, Gorson,K.C.&Ropper,A.H., 2001
An ALS-Like Syndrome with New HIV Infection and Complete Response to Antiretroviral Therapy
Neurol 57:1094-1097,945, MacGowan,D.J.L.,et al, 2001
Reversible ALS-Like Disorder in HIV Infection
Neurol 57:995-1001,945, Moulignier,A.,et al, 2001
Autologous Hematopoietic Stem Cell Transplantation Suppresses Gd-enhanced MRI activity in MS
Neurol 57:62-68, Mancardi,G.L.,et al, 2001
A Three-item Scale for the Early Prediction of Stroke Recovery
Lancet 357:2095-2099, Baird,A.E.,et al, 2001
PRISMS-4: Long-Term Efficacy of Interferon-B-1a in Relapsing MS
Neurol 56:1628-1636,1620, The PRISMS Study Group, 2001
Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
Arch Neurol 58:1299-1300,1301, Pachner,A.R., 2001
The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta
Arch Neurol 58:1297-1298,1301, Rice,G., 2001
Inclusiong Body Myositis Mimicking Motor Neuron Disease
Arch Neurol 58:1253-1256, Dabby,R.,et al, 2001
Narcolepsy Associated with Other Central Nervous System Disorders
Neurol 57:539-541, Malik,S.,et al, 2001
Handicap After Acute Whiplash Injury
Neurol 56:1637-1643, Kasch,H.,et al, 2001